Enanta Sets Chief Executive Succession Search

Company Enanta Pharmaceuticals Event Type CEO retirement and COO appointment (source-gap recovery) Modality Small molecules (virology and immunology) Asset Company-wide (zelicapavir; KIT, STAT6, MRGPRX2 programs) Target RSV; KIT; STAT6; MRGPRX2 Disease Area RSV and immunology Summary Source-gap recovery: on 28 October Enanta announced that Jay…